Designing drug delivery systems for cell therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: RNA Interference and Gene Delivery · 3D Printing in Biomedical Research · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Martino, M. et al. CART-cell therapy: recent advances and new evidence in multiple myeloma. Cancers 13, 2639 (2021).10.3390/cancers13112639 ↗
2. Sivandzade, F. & Cucullo, L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int. J. Mol. Sci. 22, 2153 (2021).10.3390/ijms22042153 ↗
3. Kitada, T., DiAndreth, B., Teague, B. & Weiss, R. Programming gene and engineered-cell therapies with synthetic biology. Science 359, eaad1067 (2018).10.1126/science.aad1067 ↗
4. Weber, E. W., Maus, M. V. & Mackall, C. L. The emerging landscape of immune cell therapies. Cell 181, 46–62 (2020). This perspective provides an overview of current developments in immune cell therapies for cancer, infectious diseases and autoimmunity, and highlights cellular engineering advances addressing key challenges.10.1016/j.cell.2020.03.001 ↗
5. Fischbach, M. A., Bluestone, J. A. & Lim, W. A. Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med. 5, 179ps7 (2013).10.1126/scitranslmed.3005568 ↗
6. Zhao, Z., Ukidve, A., Kim, J. & Mitragotri, S. Targeting strategies for tissue-specific drug delivery. Cell 181, 151–167 (2020).10.1016/j.cell.2020.02.001 ↗
7. Mount, N. M., Ward, S. J., Kefalas, P. & Hyllner, J. Cell-based therapy technology classifications and translational challenges. Philos. Trans. R. Soc. B: Biol. Sci. 370, 20150017 (2015).10.1098/rstb.2015.0017 ↗
8. Wang, L. L. W. et al. Cell therapies in the clinic. Bioeng. Transl. Med. 6, e10214 (2021). This review highlights the diversity and advantages of cell therapies, discusses 28 globally approved products and their clinical uses, analyses more than 1,700 active clinical trials and addresses the major biological, manufacturing and regulatory challenges in their clinical translation.10.1002/btm2.10214 ↗
9. Vargason, A. M., Anselmo, A. C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951–967 (2021).10.1038/s41551-021-00698-w ↗
10. Wang, H. & Mooney, D. J. Biomaterial-assisted targeted modulation of immune cells in cancer treatment. Nat. Mater. 17, 761–772 (2018).10.1038/s41563-018-0147-9 ↗
11. Li, Z. et al. Cell‐based delivery systems: emerging carriers for immunotherapy. Adv. Funct. Mater. 31, 2100088 (2021).10.1002/adfm.202100088 ↗
12. Yang, L., Yang, Y., Chen, Y., Xu, Y. & Peng, J. Cell-based drug delivery systems and their in vivo fate. Adv. Drug Deliv. Rev. 187, 114394 (2022).10.1016/j.addr.2022.114394 ↗
13. Li, J. et al. Implantable and injectable biomaterial scaffolds for cancer immunotherapy. Front. Bioeng. Biotechnol. 8, 612950 (2020).10.3389/fbioe.2020.612950 ↗
14. Adeyemi, S. A. & Choonara, Y. E. Current advances in cell therapeutics: a biomacromolecules application perspective. Expert. Opin. Drug. Deliv. 19, 521–538 (2022).10.1080/17425247.2022.2064844 ↗
15. Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).10.1038/s41571-023-00754-1 ↗
16. Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood cancer J. 11, 69 (2021).10.1038/s41408-021-00459-7 ↗
17. Arjomandnejad, M., Kopec, A. L. & Keeler, A. M. CAR-T regulatory (CAR-Treg) cells: engineering and applications. Biomedicines 10, 287 (2022).10.3390/biomedicines10020287 ↗
18. Romano, M., Fanelli, G., Albany, C. J., Giganti, G. & Lombardi, G. Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity. Front. Immunol. 10, 43 (2019).10.3389/fimmu.2019.00043 ↗
19. Zhang, L., Meng, Y., Feng, X. & Han, Z. CAR-NK cells for cancer immunotherapy: from bench to bedside. Biomarker Res. 10, 1–19 (2022).10.1186/s40364-022-00364-6 ↗
20. Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell–cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat. Immunol. 21, 835–847 (2020).10.1038/s41590-020-0728-z ↗
21. Na, Y. R., Kim, S. W. & Seok, S. H. A new era of macrophage-based cell therapy. Exp. Mol. Med. 55, 1945–1954 (2023).10.1038/s12276-023-01068-z ↗
22. Lee, S., Kivimäe, S., Dolor, A. & Szoka, F. C. Macrophage-based cell therapies: the long and winding road. J. Control. Rel. 240, 527–540 (2016).10.1016/j.jconrel.2016.07.018 ↗
23. Hoang, D. M. et al. Stem cell-based therapy for human diseases. Signal. Transduct. Target. Ther. 7, 272 (2022).10.1038/s41392-022-01134-4 ↗
24. Zakrzewski, W., Dobrzyński, M., Szymonowicz, M. & Rybak, Z. Stem cells: past, present, and future. Stem Cell Res. Ther. 10, 1–22 (2019).10.1186/s13287-019-1165-5 ↗
25. Basile, G. et al. Emerging diabetes therapies: bringing back the β-cells. Mol. Metab. 60, 101477 (2022).10.1016/j.molmet.2022.101477 ↗
26. Yu, H., Yang, Z., Li, F., Xu, L. & Sun, Y. Cell-mediated targeting drugs delivery systems. Drug. Deliv. 27, 1425–1437 (2020).10.1080/10717544.2020.1831103 ↗
27. Yousefpour, P., Ni, K. & Irvine, D. J. Targeted modulation of immune cells and tissues using engineered biomaterials. Nat. Rev. Bioeng. 1, 107–124 (2023).10.1038/s44222-022-00016-2 ↗
28. Li, R., Chen, Z., Li, J., Dai, Z. & Yu, Y. Nano-drug delivery systems for T cell-based immunotherapy. Nano Today 46, 101621 (2022).10.1016/j.nantod.2022.101621 ↗
29. Ahn, Y. H. et al. A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy. Biomaterials 247, 119960 (2020).10.1016/j.biomaterials.2020.119960 ↗
30. Prakash, S. et al. Polymer micropatches as natural killer cell engagers for tumor therapy. ACS Nano 17, 15918–15930 (2023).10.1021/acsnano.3c03980 ↗
31. Sung, S., Steele, L. A., Risser, G. E. & Spiller, K. L. Biomaterial-assisted macrophage cell therapy for regenerative medicine. Adv. Drug Deliv. Rev. 199, 114979 (2023).10.1016/j.addr.2023.114979 ↗
32. Liang, T. et al. Recent advances in macrophage-mediated drug delivery systems. Int. J. Nanomed. 16, 2703 (2021).10.2147/IJN.S298159 ↗
33. Li, Y. et al. Clinical progress and advanced research of red blood cells based drug delivery system. Biomaterials 279, 121202 (2021).10.1016/j.biomaterials.2021.121202 ↗
34. Kharbikar, B. N., Mohindra, P. & Desai, T. A. Biomaterials to enhance stem cell transplantation. Cell Stem Cell 29, 692–721 (2022).10.1016/j.stem.2022.04.002 ↗
35. Quizon, M. J. & García, A. J. Engineering β cell replacement therapies for type 1 diabetes: biomaterial advances and considerations for macroscale constructs. Annu. Rev. Pathol. Mech. Dis. 17, 485–513 (2022).10.1146/annurev-pathol-042320-094846 ↗
36. Adebowale, K. et al. Materials for cell surface engineering. Adv. Mater. https://doi.org/10.1002/adma.202210059 (2023). This review summarizes recent advances in decorating cell surfaces with nanoparticles, microparticles and polymeric coatings, focusing on enhancing carrier cells and their therapeutic effects.10.1002/adma.202210059 ↗
37. Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A. & Irvine, D. J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat. Med. 16, 1035–1041 (2010).10.1038/nm.2198 ↗
38. Tang, L. et al. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery. Nat. Biotechnol. 36, 707–716 (2018).10.1038/nbt.4181 ↗
39. Scott, M. D., Murad, K. L., Koumpouras, F., Talbot, M. & Eaton, J. W. Chemical camouflage of antigenic determinants: stealth erythrocytes. Proc. Natl Acad. Sci. USA 94, 7566–7571 (1997).10.1073/pnas.94.14.7566 ↗
40. Pan, C. et al. Polymerization‐mediated multifunctionalization of living cells for enhanced cell‐based therapy. Adv. Mater. 33, 2007379 (2021).10.1002/adma.202007379 ↗
41. Shields, C. W. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020).10.1126/sciadv.aaz6579 ↗
42. Kapate, N. et al. Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury. PNAS Nexus 3, pgad434 (2024).10.1093/pnasnexus/pgad434 ↗
43. Kapate, N. et al. Polymer backpack‐loaded tissue infiltrating monocytes for treating cancer. Adv. Healthc. Mater. 2304144 https://doi.org/10.1002/adhm.202304144 (2024).10.1002/adhm.202304144 ↗
44. Farina, M., Alexander, J. F., Thekkedath, U., Ferrari, M. & Grattoni, A. Cell encapsulation: overcoming barriers in cell transplantation in diabetes and beyond. Adv. Drug Deliv. Rev. 139, 92–115 (2019). This review summarizes encapsulation strategies from academic and industrial research, including technologies in advanced preclinical and clinical phases, and highlights stimulus-responsive systems for improved therapeutic delivery in cell transplantation.10.1016/j.addr.2018.04.018 ↗
45. Sun, L. et al. Induced cardiomyocytes-integrated conductive microneedle patch for treating myocardial infarction. Chem. Eng. J. 414, 128723 (2021).10.1016/j.cej.2021.128723 ↗
46. Lathuiliere, A. et al. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies. Brain 139, 1587–1604 (2016).10.1093/brain/aww036 ↗
47. Yang, L. et al. A biodegradable hybrid inorganic nanoscaffold for advanced stem cell therapy. Nat. Commun. 9, 3147 (2018).10.1038/s41467-018-05599-2 ↗
48. Ye, Y. et al. Microneedles integrated with pancreatic cells and synthetic glucose‐signal amplifiers for smart insulin delivery. Adv. Mater. 28, 3115–3121 (2016).10.1002/adma.201506025 ↗
49. Xue, D., Hsu, E., Fu, Y.-X. & Peng, H. Next-generation cytokines for cancer immunotherapy. Antib. Ther. 4, 123–133 (2021).
50. Jones, R. B. et al. Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials 117, 44–53 (2017).10.1016/j.biomaterials.2016.11.048 ↗
51. Xie, Y.-Q. et al. Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells. Biomater. Sci. 7, 1345–1357 (2019).10.1039/C8BM01556B ↗
52. Eskandari, S. K. et al. Regulatory T cells engineered with TCR signaling-responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter. Sci. Transl. Med. 12, eaaw4744 (2020).10.1126/scitranslmed.aaw4744 ↗
53. Liu, Y. et al. Cytokine conjugation to enhance T cell therapy. Proc. Natl Acad. Sci. USA 120, e2213222120 (2023).10.1073/pnas.2213222120 ↗
54. Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41–46 (2020).10.1038/s41565-019-0600-1 ↗
55. Stephan, M. T., Stephan, S. B., Bak, P., Chen, J. & Irvine, D. J. Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. Biomaterials 33, 5776–5787 (2012).10.1016/j.biomaterials.2012.04.029 ↗
56. Hao, M. et al. Combination of metabolic intervention and T cell therapy enhances solid tumor immunotherapy. Sci. Transl. Med. 12, eaaz6667 (2020).10.1126/scitranslmed.aaz6667 ↗
57. Trowbridge, J. J., Xenocostas, A., Moon, R. T. & Bhatia, M. Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. Nat. Med. 12, 89–98 (2006).10.1038/nm1339 ↗
58. Loukogeorgakis, S. P. et al. Donor cell engineering with GSK3 inhibitor-loaded nanoparticles enhances engraftment after in utero transplantation. Blood 134, 1983–1995 (2019).10.1182/blood.2019001037 ↗
59. Yu, D. et al. Hydrogen‐bonded organic framework (HOF)‐based single‐neural stem cell encapsulation and transplantation to remodel impaired neural networks. Angew. Chem. 134, e202201485 (2022).10.1002/ange.202201485 ↗
60. Kapate, N. et al. A backpack-based myeloid cell therapy for multiple sclerosis. Proc. Natl Acad. Sci. USA 120, e2221535120 (2023).10.1073/pnas.2221535120 ↗
61. Liu, S. et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J. Hematol. Oncol. 14, 1–17 (2021).10.1186/s13045-020-01014-w ↗
62. Kumbhojkar, N. et al. Neutrophils bearing adhesive polymer micropatches as a drug-free cancer immunotherapy. Nat. Biomed. Eng. 8, 579–592 (2024).10.1038/s41551-024-01180-z ↗
63. Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847–856 (2018).10.1038/nbt.4195 ↗
64. Chen, X. et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy. Mol. Ther. Oncol. 21, 144–157 (2021).10.1016/j.omto.2021.03.014 ↗
65. Ghasemi, A. et al. Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy. Nat. Cancer 5, 240–261 (2023).10.1038/s43018-023-00668-y ↗
66. Agarwalla, P. et al. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat. Biotechnol. 40, 1250–1258 (2022).10.1038/s41587-022-01245-x ↗
67. Anselmo, A. C. et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7, 11129–11137 (2013).10.1021/nn404853z ↗
68. Anselmo, A. C. et al. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: synergy between physical, chemical and biological approaches. Biomaterials 68, 1–8 (2015).10.1016/j.biomaterials.2015.07.043 ↗
69. Brenner, J. S. et al. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude. Nat. Commun. 9, 2684 (2018).10.1038/s41467-018-05079-7 ↗
70. Ukidve, A. et al. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proc. Natl Acad. Sci. USA 117, 17727–17736 (2020).10.1073/pnas.2002880117 ↗
71. Zhao, Z., Ukidve, A., Gao, Y., Kim, J. & Mitragotri, S. Erythrocyte leveraged chemotherapy (ELeCt): nanoparticle assembly on erythrocyte surface to combat lung metastasis. Sci. Adv. 5, eaax9250 (2019).10.1126/sciadv.aax9250 ↗
72. Zhao, Z. et al. Systemic tumour suppression via the preferential accumulation of erythrocyte-anchored chemokine-encapsulating nanoparticles in lung metastases. Nat. Biomed. Eng. 5, 441–454 (2021).10.1038/s41551-020-00644-2 ↗
73. Ding, Y. et al. RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery. J. Control, Rel. 341, 702–715 (2022).10.1016/j.jconrel.2021.12.018 ↗
74. Wang, C. et al. Multifunctional theranostic red blood cells for magnetic‐field‐enhanced in vivo combination therapy of cancer. Adv. Mater. 26, 4794–4802 (2014).10.1002/adma.201400158 ↗
75. Ferguson, L. T. et al. Dual affinity to RBCs and target cells (DART) enhances both organ-and cell type-targeting of intravascular nanocarriers. ACS Nano 16, 4666–4683 (2022).10.1021/acsnano.1c11374 ↗
76. Zhao, Z. et al. Engineering of living cells with polyphenol‐functionalized biologically active nanocomplexes. Adv. Mater. 32, 2003492 (2020).10.1002/adma.202003492 ↗
77. Zhao, Z. et al. Red blood cell anchoring enables targeted transduction and re‐administration of AAV‐mediated gene therapy. Adv. Sci. 9, 2201293 (2022).10.1002/advs.202201293 ↗
78. Zelepukin, I. et al. Nanoparticle-based drug delivery via RBC-hitchhiking for the inhibition of lung metastases growth. Nanoscale 11, 1636–1646 (2019).10.1039/C8NR07730D ↗
79. Schmid, D. et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat. Commun. 8, 1–12 (2017).10.1038/s41467-017-01830-8 ↗
80. Huang, B. et al. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci. Transl. Med. 7, 291ra94 (2015).10.1126/scitranslmed.aaa5447 ↗
81. Shi, C. et al. Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of TH17 cells to Treg cells for the treatment of multiple sclerosis in mice. Adv. Mater. 35, 2210262 (2023).10.1002/adma.202210262 ↗
82. Gao, C. et al. Supramolecular macrophage–liposome marriage for cell‐hitchhiking delivery and immunotherapy of acute pneumonia and melanoma. Adv. Funct. Mater. 31, 2102440 (2021).10.1002/adfm.202102440 ↗
83. Yang, L. et al. Live macrophage-delivered doxorubicin-loaded liposomes effectively treat triple-negative breast cancer. ACS Nano 16, 9799–9809 (2022).10.1021/acsnano.2c03573 ↗
84. Im, S. et al. Harnessing the formation of natural killer–tumor cell immunological synapses for enhanced therapeutic effect in solid tumors. Adv. Mater. 32, 2000020 (2020).10.1002/adma.202000020 ↗
85. Mosquera, J., García, I. & Liz-Marzán, L. M. Cellular uptake of nanoparticles versus small molecules: a matter of size. Acc. Chem. Res. 51, 2305–2313 (2018).10.1021/acs.accounts.8b00292 ↗
86. Rennick, J. J., Johnston, A. P. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021).10.1038/s41565-021-00858-8 ↗
87. Dou, H. et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827–2835 (2006).10.1182/blood-2006-03-012534 ↗
88. Choi, M.-R. et al. A cellular Trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7, 3759–3765 (2007).10.1021/nl072209h ↗
89. Evans, M. A. et al. Macrophage‐mediated delivery of hypoxia‐activated prodrug nanoparticles. Adv. Ther. 3, 1900162 (2020).10.1002/adtp.201900162 ↗
90. Qi, Y., Yan, X., Xia, T. & Liu, S. Use of macrophage as a Trojan horse for cancer nanotheranostics. Mater. Des. 198, 109388 (2021).10.1016/j.matdes.2020.109388 ↗
91. Mantovani, A., Allavena, P., Marchesi, F. & Garlanda, C. Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug. Discov. 21, 799–820 (2022).10.1038/s41573-022-00520-5 ↗
92. Choi, J. et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 33, 4195–4203 (2012).10.1016/j.biomaterials.2012.02.022 ↗
93. De Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378–391 (2016).10.1038/nri.2016.49 ↗
94. Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013).10.1038/nri3399 ↗
95. Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692 (2017).10.1038/nnano.2017.54 ↗
96. Luo, Z. et al. Neutrophil hitchhiking for drug delivery to the bone marrow. Nat. Nanotechnol. 18, 647–656 (2023).10.1038/s41565-023-01374-7 ↗
97. Shi, M. et al. Dual functional monocytes modulate bactericidal and anti‐inflammation process for severe osteomyelitis treatment. Small 16, 1905185 (2020).10.1002/smll.201905185 ↗
98. Kim, H. et al. Gold nanoparticle‐carrying T cells for the combined immuno‐photothermal therapy. Small 19, 2301377 (2023).10.1002/smll.202301377 ↗
99. Wu, M. et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat. Commun. 9, 4777 (2018).10.1038/s41467-018-07250-6 ↗
100. Sun, P. et al. A smart nanoparticle-laden and remote-controlled self-destructive macrophage for enhanced chemo/chemodynamic synergistic therapy. ACS Nano 14, 13894–13904 (2020).10.1021/acsnano.0c06290 ↗